Yanliang Bai
Overview
Explore the profile of Yanliang Bai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
80
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Han L, Sun X, Kong J, Li J, Feng K, Bai Y, et al.
J Transl Med
. 2024 Aug;
22(1):746.
PMID: 39113144
Acute graft-versus-host disease (aGVHD) is primarily driven by allogeneic donor T cells associated with an altered composition of the host gut microbiome and its metabolites. The severity of aGVHD after...
2.
Zhang X, Liu B, Huang J, Zhang Y, Xu N, Gale R, et al.
Blood
. 2024 Jul;
144(18):1951-1961.
PMID: 39046786
Although tyrosine kinase inhibitor (TKI) therapy has markedly improved the survival of people with chronic-phase chronic myeloid leukemia (CML), 20% to 30% of people still experienced therapy failure. Data from...
3.
Guo H, Cui Y, Bai Y, Yan F, Zhang W, Chen Y, et al.
Int J Gen Med
. 2024 Jul;
17:2967-2979.
PMID: 39006913
Background: Relapsed/refractory acute myeloid leukemia (R/R-AML) has dismal prognosis due to chemotherapy resistance. Circular RNAs (circRNAs) have shown emerging roles in chemotherapy resistance in various cancers including hematologic malignancies. However,...
4.
Li W, Shi M, Zhou P, Liu Y, Liu X, Xiao X, et al.
Pediatr Blood Cancer
. 2024 Apr;
71(7):e31014.
PMID: 38644612
Background: The outcome of extramedullary infiltration (EMI) in pediatric acute myeloid leukemia (AML) is controversial, and little is known about the implications of stem cell transplantation (SCT) and gemtuzumab ozogamicin...
5.
Bai Y, Sun X, Li M, Niu X, Cao W, Niu J, et al.
Front Oncol
. 2024 Apr;
14:1342998.
PMID: 38577341
Background: mutations can be detected in premalignant hematopoietic stem cells and are primarily associated with clonal hematopoiesis of indeterminate potential; however, current evidence does not support assigning them to a...
6.
Zhang X, Xu N, Yang Y, Lin H, Liu B, Du X, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Mar;
24(6):e257-e266.
PMID: 38461040
Background: There are limited data comprehensively comparing therapy responses and outcomes among nilotinib, dasatinib, flumatinib and imatinib for newly diagnosed chronic-phase chronic myeloid leukemia in a real-world setting. Patients And...
7.
Song J, Li W, Bai Y, Zhou P, Niu J, Niu X, et al.
Ann Hematol
. 2024 Jan;
103(2):463-473.
PMID: 38183444
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive myeloid malignancy which characteristically expresses an atypical phenotype including CD123+, CD56+, and CD4+. We are aimed to investigate the...
8.
Liu X, Bai Y, Liu Y, Li W, Cui Y, Xu J, et al.
Blood Res
. 2023 Nov;
58(4):187-193.
PMID: 38031470
Background: Red blood cell distribution width/platelet count ratio (RPR) is a reliable prognostic assessment indicator for numerous diseases. However, no studies to date have examined the relationship between RPR and...
9.
Li M, Bai Y, Sun X, Wang H, Li W, Xiao X, et al.
Discov Med
. 2023 Apr;
35(175):157-167.
PMID: 37105925
Background: The red blood cell distribution width to platelet ratio (RPR) is an inflammatory marker that is a convenient and reliable prognostic indicator for several solid malignancies. However, the correlation...
10.
Zhang X, Gale R, Liu B, Huang J, Zhang Y, Du X, et al.
Leukemia
. 2023 Mar;
37(5):1166-1169.
PMID: 36973351
No abstract available.